Literature DB >> 23903407

Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles.

Daniel L J Thorek1, Michael J Evans, Sigrid V Carlsson, David Ulmert, Hans Lilja.   

Abstract

Kallikreins are a family of serine proteases with a range of tissue-specific and essential proteolytic functions. Among the best studied are the prostate tissue-specific KLK2 and KLK3 genes and their secreted protease products, human kallikrein 2, hk2, and prostate-specific antigen (PSA). Members of the so-called classic kallikreins, these highly active trypsin-like serine proteases play established roles in human reproduction. Both hK2 and PSA expression is regulated by the androgen receptor which has a fundamental role in prostate tissue development and progression of disease. This feature, combined with the ability to sensitively detect different forms of these proteins in blood and biopsies, result in a crucially important biomarker for the presence and recurrence of cancer. Emerging evidence has begun to suggest a role for these kallikreins in critical vascular events. This review discusses the established and developing biological roles of hK2 and PSA, as well as the historical and advanced use of their detection to accurately and non-invasively detect and guide treatment of prostatic disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23903407      PMCID: PMC4029064          DOI: 10.1160/TH13-04-0275

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  74 in total

1.  Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3.

Authors:  S Réhault; P Monget; S Mazerbourg; R Tremblay; N Gutman; F Gauthier; T Moreau
Journal:  Eur J Biochem       Date:  2001-05

2.  Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing.

Authors:  S R Denmeade; J Lövgren; S R Khan; H Lilja; J T Isaacs
Journal:  Prostate       Date:  2001-07-01       Impact factor: 4.104

3.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

4.  Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146.

Authors:  P Nurmikko; K Pettersson; T Piironen; J Hugosson; H Lilja
Journal:  Clin Chem       Date:  2001-08       Impact factor: 8.327

5.  Prostate-cancer mortality at 11 years of follow-up.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Alvaro Páez; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Sigrid Carlsson; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Paula M Kujala; Bert G Blijenberg; Ulf-Hakan Stenman; Andreas Huber; Kimmo Taari; Matti Hakama; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

6.  A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.

Authors:  Andrew J Vickers; Amit Gupta; Caroline J Savage; Kim Pettersson; Anders Dahlin; Anders Bjartell; Jonas Manjer; Peter T Scardino; David Ulmert; Hans Lilja
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-12-08       Impact factor: 4.254

7.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

Review 8.  Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis.

Authors:  Andrew W Roddam; Michael J Duffy; Freddie C Hamdy; Anthony Milford Ward; Julietta Patnick; Christopher P Price; Janet Rimmer; Cathie Sturgeon; Peter White; Naomi E Allen
Journal:  Eur Urol       Date:  2005-09       Impact factor: 20.096

9.  Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo.

Authors:  A H Fortier; J W Holaday; H Liang; C Dey; D K Grella; J Holland-Linn; H Vu; S M Plum; B J Nelson
Journal:  Prostate       Date:  2003-08-01       Impact factor: 4.104

10.  Novel small molecule inhibitors for prostate-specific antigen.

Authors:  Hannu Koistinen; Gerd Wohlfahrt; Johanna M Mattsson; Ping Wu; Juhani Lahdenperä; Ulf-Håkan Stenman
Journal:  Prostate       Date:  2008-08-01       Impact factor: 4.104

View more
  14 in total

1.  Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution.

Authors:  Oskar Vilhelmsson-Timmermand; Elmer Santos; Daniel L J Thorek; Susan Evans-Axelsson; Anders Bjartell; Hans Lilja; Steven M Larson; Sven-Erik Strand; Thuy A Tran; David Ulmert
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

Review 2.  The role of the prostate in male fertility, health and disease.

Authors:  Paolo Verze; Tommaso Cai; Stefano Lorenzetti
Journal:  Nat Rev Urol       Date:  2016-06-01       Impact factor: 14.432

3.  Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis.

Authors:  Daniel L J Thorek; Philip A Watson; Sang-Gyu Lee; Anson T Ku; Stylianos Bournazos; Katharina Braun; Kwanghee Kim; Kjell Sjöström; Michael G Doran; Urpo Lamminmäki; Elmer Santos; Darren Veach; Mesruh Turkekul; Emily Casey; Jason S Lewis; Diane S Abou; Marise R H van Voss; Peter T Scardino; Sven-Erik Strand; Mary L Alpaugh; Howard I Scher; Hans Lilja; Steven M Larson; David Ulmert
Journal:  Sci Transl Med       Date:  2016-11-30       Impact factor: 17.956

4.  Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer.

Authors:  Aaron M LeBeau; Samuel R Denmeade
Journal:  Mol Cancer Ther       Date:  2014-12-23       Impact factor: 6.261

5.  Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.

Authors:  Daniel L J Thorek; Anson T Ku; Nicholas Mitsiades; Darren Veach; Philip A Watson; Dipti Metha; Sven-Erik Strand; Sai Kiran Sharma; Jason S Lewis; Diane S Abou; Hans G Lilja; Steven M Larson; Michael R McDevitt; David Ulmert
Journal:  Clin Cancer Res       Date:  2018-09-25       Impact factor: 12.531

6.  A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer.

Authors:  Shane Stegeman; Ernest Amankwah; Kerenaftali Klein; Tracy A O'Mara; Donghwa Kim; Hui-Yi Lin; Jennifer Permuth-Wey; Thomas A Sellers; Srilakshmi Srinivasan; Rosalind Eeles; Doug Easton; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch; Kenneth Muir; Graham G Giles; Fredrik Wiklund; Henrik Gronberg; Christopher A Haiman; Johanna Schleutker; Børge G Nordestgaard; Ruth C Travis; David Neal; Paul Pharoah; Kay-Tee Khaw; Janet L Stanford; William J Blot; Stephen Thibodeau; Christiane Maier; Adam S Kibel; Cezary Cybulski; Lisa Cannon-Albright; Hermann Brenner; Radka Kaneva; Manuel R Teixeira; Amanda B Spurdle; Judith A Clements; Jong Y Park; Jyotsna Batra
Journal:  Cancer Discov       Date:  2015-02-17       Impact factor: 39.397

Review 7.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

8.  Enrichment of the Cancer Stem Phenotype in Sphere Cultures of Prostate Cancer Cell Lines Occurs through Activation of Developmental Pathways Mediated by the Transcriptional Regulator ΔNp63α.

Authors:  Roberto Portillo-Lara; Mario Moisés Alvarez
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

9.  Proteolytic activity of prostate-specific antigen (PSA) towards protein substrates and effect of peptides stimulating PSA activity.

Authors:  Johanna M Mattsson; Suvi Ravela; Can Hekim; Magnus Jonsson; Johan Malm; Ale Närvänen; Ulf-Håkan Stenman; Hannu Koistinen
Journal:  PLoS One       Date:  2014-09-19       Impact factor: 3.240

10.  Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.

Authors:  Oskar Vilhelmsson Timmermand; David Ulmert; Susan Evans-Axelsson; Kim Pettersson; Anders Bjartell; Hans Lilja; Sven-Erik Strand; Thuy A Tran
Journal:  EJNMMI Res       Date:  2014-09-19       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.